Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Early-stage Breast Cancer|HER2 Positive Breast Cancer|Hormone Receptor Positive
Interventions: DRUG: Neratinib|DRUG: Loperamide|DRUG: Colesevelam
Sponsor: Spanish Breast Cancer Research Group
Collaborators: Puma Biotechnology, Inc.|Pierre Fabre Laboratories